
- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
-
Adresse
Centre d'information et de documentation
Horaires
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexLundi au Vendredi
Contact
9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Adresse
Détail de l'auteur
Auteur Nicholas J. BOWDEN |
Documents disponibles écrits par cet auteur (3)



Autism spectrum disorder/Takiw?tanga: An Integrated Data Infrastructure-based approach to autism spectrum disorder research in New Zealand / Nicholas J. BOWDEN in Autism, 24-8 (November 2020)
![]()
[article]
Titre : Autism spectrum disorder/Takiw?tanga: An Integrated Data Infrastructure-based approach to autism spectrum disorder research in New Zealand Type de document : Texte imprimé et/ou numérique Auteurs : Nicholas J. BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Richard AUDAS, Auteur ; Barry MILNE, Auteur ; Kirsten SMILER, Auteur ; Hilary STACE, Auteur ; Barry TAYLOR, Auteur ; Sheree GIBB, Auteur Article en page(s) : p.2213-2227 Langues : Anglais (eng) Mots-clés : *Integrated Data Infrastructure *autism spectrum disorder *big data *case identification *mental health Index. décimale : PER Périodiques Résumé : New Zealand has few estimates of the prevalence autism spectrum disorder and no national registry or data set to identify and track cases. This hinders the ability to make informed, evidence-based decisions relating to autism spectrum disorder. In this study, we utilised linked health and non-health data to develop a method for identifying cases of autism spectrum disorder among children and young people in New Zealand. In addition, we examined rates of co-occurring mental health, neurodevelopmental and related conditions among this cohort and compared these to the general population. The method identified almost 10,000 children and young people with autism spectrum disorder in New Zealand. Co-occurring mental health or related problems were found in over 68% of this group (nearly seven times higher than the general population), and around half were identified with multiple co-occurring conditions. The most frequently identified conditions were intellectual disability, disruptive behaviours and emotional problems. We have developed a useful method for monitoring service and treatment-related trends, number and types of co-occurring conditions and examining social outcomes among individuals with autism spectrum disorder. While the method may underestimate the prevalence of autism spectrum disorder in New Zealand, it provides a significant step towards establishing a more comprehensive evidence base to inform autism spectrum disorder-related policy. En ligne : http://dx.doi.org/10.1177/1362361320939329 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=431
in Autism > 24-8 (November 2020) . - p.2213-2227[article] Autism spectrum disorder/Takiw?tanga: An Integrated Data Infrastructure-based approach to autism spectrum disorder research in New Zealand [Texte imprimé et/ou numérique] / Nicholas J. BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Richard AUDAS, Auteur ; Barry MILNE, Auteur ; Kirsten SMILER, Auteur ; Hilary STACE, Auteur ; Barry TAYLOR, Auteur ; Sheree GIBB, Auteur . - p.2213-2227.
Langues : Anglais (eng)
in Autism > 24-8 (November 2020) . - p.2213-2227
Mots-clés : *Integrated Data Infrastructure *autism spectrum disorder *big data *case identification *mental health Index. décimale : PER Périodiques Résumé : New Zealand has few estimates of the prevalence autism spectrum disorder and no national registry or data set to identify and track cases. This hinders the ability to make informed, evidence-based decisions relating to autism spectrum disorder. In this study, we utilised linked health and non-health data to develop a method for identifying cases of autism spectrum disorder among children and young people in New Zealand. In addition, we examined rates of co-occurring mental health, neurodevelopmental and related conditions among this cohort and compared these to the general population. The method identified almost 10,000 children and young people with autism spectrum disorder in New Zealand. Co-occurring mental health or related problems were found in over 68% of this group (nearly seven times higher than the general population), and around half were identified with multiple co-occurring conditions. The most frequently identified conditions were intellectual disability, disruptive behaviours and emotional problems. We have developed a useful method for monitoring service and treatment-related trends, number and types of co-occurring conditions and examining social outcomes among individuals with autism spectrum disorder. While the method may underestimate the prevalence of autism spectrum disorder in New Zealand, it provides a significant step towards establishing a more comprehensive evidence base to inform autism spectrum disorder-related policy. En ligne : http://dx.doi.org/10.1177/1362361320939329 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=431 Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study / Laurie K. MCLAY in Research in Autism Spectrum Disorders, 93 (May 2022)
![]()
[article]
Titre : Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study Type de document : Texte imprimé et/ou numérique Auteurs : Laurie K. MCLAY, Auteur ; Nicholas J. BOWDEN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Rhiannon BRAUND, Auteur ; Philip J. SCHLUTER, Auteur Article en page(s) : 101948 Langues : Anglais (eng) Mots-clés : Autism Attention deficit hyperactivity disorder Melatonin Sleep Polypharmacy Index. décimale : PER Périodiques Résumé : Background Chronic insomnia is common in children with autism and Attention Deficit Hyperactivity Disorder (ADHD). Melatonin is often used to treat childhood insomnia. However, it may interact with other medications being used to manage other symptoms. This pharmacoepidemiological study examined the rates of general and psychotropic polypharmacy among children with autism and/or ADHD, stratified by melatonin dispensing. The impact of sociodemographic and child characteristics on such dispensing was also examined. Method Linked national health and pharmaceutical administrative data for children aged 0?18 years in 2019 was utilized. Overall and melatonin dispensing stratified polypharmacy rates were calculated. Ordinal logistic regression models were employed to compare groups and adjust for confounders. Results Data were acquired for 10,209 children with autism (18.5% were dispensed melatonin), 5970 with ADHD (22.3% were dispensed melatonin), 2064 with autism and ADHD (29.9% were dispensed melatonin), and 1156,296 without a diagnosis of autism or ADHD (a control group; 0.5% dispensed melatonin). Relative to controls, rates of melatonin dispensing and polypharmacy were higher in children with autism and ADHD, and highest among those with both conditions. Children dispensed melatonin experienced the greatest rates of polypharmacy, especially if they had both autism and ADHD. Conclusions Children with autism and ADHD experience significant medication burden and potentially adverse interactions between psychotropic and sleep-related medication, raising important questions regarding their clinical care. En ligne : https://doi.org/10.1016/j.rasd.2022.101948 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475
in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101948[article] Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study [Texte imprimé et/ou numérique] / Laurie K. MCLAY, Auteur ; Nicholas J. BOWDEN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Rhiannon BRAUND, Auteur ; Philip J. SCHLUTER, Auteur . - 101948.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101948
Mots-clés : Autism Attention deficit hyperactivity disorder Melatonin Sleep Polypharmacy Index. décimale : PER Périodiques Résumé : Background Chronic insomnia is common in children with autism and Attention Deficit Hyperactivity Disorder (ADHD). Melatonin is often used to treat childhood insomnia. However, it may interact with other medications being used to manage other symptoms. This pharmacoepidemiological study examined the rates of general and psychotropic polypharmacy among children with autism and/or ADHD, stratified by melatonin dispensing. The impact of sociodemographic and child characteristics on such dispensing was also examined. Method Linked national health and pharmaceutical administrative data for children aged 0?18 years in 2019 was utilized. Overall and melatonin dispensing stratified polypharmacy rates were calculated. Ordinal logistic regression models were employed to compare groups and adjust for confounders. Results Data were acquired for 10,209 children with autism (18.5% were dispensed melatonin), 5970 with ADHD (22.3% were dispensed melatonin), 2064 with autism and ADHD (29.9% were dispensed melatonin), and 1156,296 without a diagnosis of autism or ADHD (a control group; 0.5% dispensed melatonin). Relative to controls, rates of melatonin dispensing and polypharmacy were higher in children with autism and ADHD, and highest among those with both conditions. Children dispensed melatonin experienced the greatest rates of polypharmacy, especially if they had both autism and ADHD. Conclusions Children with autism and ADHD experience significant medication burden and potentially adverse interactions between psychotropic and sleep-related medication, raising important questions regarding their clinical care. En ligne : https://doi.org/10.1016/j.rasd.2022.101948 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475 National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder / Nicholas J. BOWDEN in Research in Autism Spectrum Disorders, 78 (October 2020)
![]()
[article]
Titre : National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Nicholas J. BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Rhiannon BRAUND, Auteur Article en page(s) : 101642 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Children Adolescents Pharmacotherapy Integrated Data Infrastructure Polypharmacy Index. décimale : PER Périodiques Résumé : Background International data and guidance on prescribing for children and young people with autism spectrum disorder (ASD) are limited. National administrative datasets such as the New Zealand Integrated Data Infrastructure (IDI) may offer a cost-effective and sustainable way to monitor prescribing trends in the context of clinical and systemic change. Method Medication dispensing for New Zealand children and young people with ASD was explored using the IDI. Psychotropic and non-psychotropic medication dispensing rates, and rates of polypharmacy within a one-year period were examined. Comparisons of medication use were made to children and young people with another neurodevelopmental condition, attention deficit hyperactivity disorder (ADHD), and the general population. Results The vast majority (83 %) of children and young people with ASD were prescribed medication within a one-year period and they received a mean of four unique medications. High dispensing of antihistamine, asthma, gastrointestinal, and psychotropic medications was observed. Just over half (57 %) of those with ASD experienced polypharmacy of three or more medications, and 11 % of 10 or more. Medication dispensing rates were significantly higher among the ASD group compared to those with ADHD and the general population. Polypharmacy rates were higher among both the ASD and ADHD group compared to the general population. Conclusions It is clear that New Zealand children and young people with ASD experience a significant and disproportionate medication burden. Although further investigation is needed to fully understand underlying reasons and clinical implications, the IDI appears to be a valuable means of monitoring prescribing trends over time. En ligne : https://doi.org/10.1016/j.rasd.2020.101642 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=433
in Research in Autism Spectrum Disorders > 78 (October 2020) . - 101642[article] National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder [Texte imprimé et/ou numérique] / Nicholas J. BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Rhiannon BRAUND, Auteur . - 101642.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 78 (October 2020) . - 101642
Mots-clés : Autism spectrum disorder Children Adolescents Pharmacotherapy Integrated Data Infrastructure Polypharmacy Index. décimale : PER Périodiques Résumé : Background International data and guidance on prescribing for children and young people with autism spectrum disorder (ASD) are limited. National administrative datasets such as the New Zealand Integrated Data Infrastructure (IDI) may offer a cost-effective and sustainable way to monitor prescribing trends in the context of clinical and systemic change. Method Medication dispensing for New Zealand children and young people with ASD was explored using the IDI. Psychotropic and non-psychotropic medication dispensing rates, and rates of polypharmacy within a one-year period were examined. Comparisons of medication use were made to children and young people with another neurodevelopmental condition, attention deficit hyperactivity disorder (ADHD), and the general population. Results The vast majority (83 %) of children and young people with ASD were prescribed medication within a one-year period and they received a mean of four unique medications. High dispensing of antihistamine, asthma, gastrointestinal, and psychotropic medications was observed. Just over half (57 %) of those with ASD experienced polypharmacy of three or more medications, and 11 % of 10 or more. Medication dispensing rates were significantly higher among the ASD group compared to those with ADHD and the general population. Polypharmacy rates were higher among both the ASD and ADHD group compared to the general population. Conclusions It is clear that New Zealand children and young people with ASD experience a significant and disproportionate medication burden. Although further investigation is needed to fully understand underlying reasons and clinical implications, the IDI appears to be a valuable means of monitoring prescribing trends over time. En ligne : https://doi.org/10.1016/j.rasd.2020.101642 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=433